JP2024505274A5 - - Google Patents

Info

Publication number
JP2024505274A5
JP2024505274A5 JP2023547031A JP2023547031A JP2024505274A5 JP 2024505274 A5 JP2024505274 A5 JP 2024505274A5 JP 2023547031 A JP2023547031 A JP 2023547031A JP 2023547031 A JP2023547031 A JP 2023547031A JP 2024505274 A5 JP2024505274 A5 JP 2024505274A5
Authority
JP
Japan
Prior art keywords
amino acid
acid sequence
seq
rmva
vector according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023547031A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024505274A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/014970 external-priority patent/WO2022169895A1/en
Publication of JP2024505274A publication Critical patent/JP2024505274A/ja
Publication of JP2024505274A5 publication Critical patent/JP2024505274A5/ja
Pending legal-status Critical Current

Links

JP2023547031A 2021-02-02 2022-02-02 ワクチン接種中のt細胞プライミングの強化において使用されるウイルスコンストラクト Pending JP2024505274A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163144834P 2021-02-02 2021-02-02
US63/144,834 2021-02-02
PCT/US2022/014970 WO2022169895A1 (en) 2021-02-02 2022-02-02 Viral constructs for use in enhancing t-cell priming during vaccination

Publications (2)

Publication Number Publication Date
JP2024505274A JP2024505274A (ja) 2024-02-05
JP2024505274A5 true JP2024505274A5 (cg-RX-API-DMAC7.html) 2025-02-06

Family

ID=82741782

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023547031A Pending JP2024505274A (ja) 2021-02-02 2022-02-02 ワクチン接種中のt細胞プライミングの強化において使用されるウイルスコンストラクト

Country Status (12)

Country Link
US (1) US20240344082A1 (cg-RX-API-DMAC7.html)
EP (1) EP4288076A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024505274A (cg-RX-API-DMAC7.html)
KR (1) KR20240001116A (cg-RX-API-DMAC7.html)
CN (1) CN117177763A (cg-RX-API-DMAC7.html)
AU (1) AU2022215566A1 (cg-RX-API-DMAC7.html)
BR (1) BR112023015467A2 (cg-RX-API-DMAC7.html)
CA (1) CA3206004A1 (cg-RX-API-DMAC7.html)
IL (1) IL304805A (cg-RX-API-DMAC7.html)
MX (1) MX2023009008A (cg-RX-API-DMAC7.html)
TW (1) TW202246514A (cg-RX-API-DMAC7.html)
WO (1) WO2022169895A1 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111533785B (zh) * 2020-02-11 2022-03-08 北京市肿瘤防治研究所 靶向免疫检查点tim3结合肽及其应用
CA3167052A1 (en) 2020-02-14 2021-08-19 Mary Jo Hauser Vaccines and uses thereof to induce an immune response to sars-cov2
WO2024206243A1 (en) * 2023-03-24 2024-10-03 Geovax. Inc. Pan-betacoronavirus vaccines and uses thereof
WO2025072383A1 (en) * 2023-09-25 2025-04-03 The Broad Institute, Inc. Viral open reading frames, uses thereof, and methods of detecting the same
CN117904069B (zh) * 2024-01-04 2025-07-15 华中农业大学 VirEN蛋白介导的DNA拼接和基因编辑方法
GB202409284D0 (en) * 2024-06-27 2024-08-14 Univ Oxford Innovation Ltd Mrna platform

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7045313B1 (en) 1982-11-30 2006-05-16 The United States Of America As Represented By The Department Of Health And Human Services Recombinant vaccinia virus containing a chimeric gene having foreign DNA flanked by vaccinia regulatory DNA
UA82479C2 (uk) 2002-05-16 2008-04-25 Бавариан Нордика А/С Міжгенні регіони як сайти вставки в геном модифікованого вірусу коров'ячої віспи ankara (mva)
DK2402451T3 (en) 2006-08-25 2018-06-25 The Government Of The Us Secretary Department Of Health And Human Services Method for Stabilizing a DNA Insert in a Recombinant Vaccine Vector
US20100305002A1 (en) 2009-04-27 2010-12-02 Roswell Park Cancer Institute Reagents and Methods for Producing Bioactive Secreted Peptides
WO2011047324A1 (en) 2009-10-16 2011-04-21 The U.S.A. As Represented By The Secretary , Department Of Health And Human Services . Recombinant modified vaccinia ankara (mva) vaccinia virus containing restructured insertion sites
US9884075B2 (en) * 2014-01-16 2018-02-06 California Institute Of Technology Domain-swap T cell receptors
DK3552615T3 (da) * 2014-07-16 2022-02-14 Transgene Onkolytisk virus til ekspression af immun-checkpoint-modulatorer
EP4122492A1 (en) * 2015-02-25 2023-01-25 Memorial Sloan Kettering Cancer Center Use of inactivated nonreplicating modified vaccinia virus ankara (mva)as monoimmunotherapy or in combination with immune checkpoint blocking agents for solid tumors
US10799555B2 (en) 2016-09-15 2020-10-13 Leidos, Inc. PD-1 peptide inhibitors
DK3512536T3 (da) 2016-09-15 2020-11-23 Leidos Inc Pd-1-peptidinhibitorer
IL319942A (en) 2016-11-02 2025-05-01 Evans David Synthetic chimeric poxviruses, methods for their production, compositions containing them and uses thereof
EP3630807B1 (en) 2017-05-25 2025-08-13 Leidos, Inc. Pd-1 and ctla-4 dual inhibitor peptides
US20210155955A1 (en) * 2018-04-11 2021-05-27 Cancer Targeting Systems, Inc. Therapeutic constructs for treating cancer
CA3099330A1 (en) 2018-05-02 2019-11-07 Tonix Pharma Holdings Limited Synthetic chimeric vaccinia virus
US12559526B2 (en) * 2018-10-15 2026-02-24 The Regents Of The University Of California Complement component 1s (C1s) deficient cells for production of vaccines and biopharmaceutical proteins
CN115397998A (zh) 2020-02-03 2022-11-25 希望之城 由天然或合成dna产生的基于痘病毒的载体及其用途

Similar Documents

Publication Publication Date Title
JP2022160401A5 (cg-RX-API-DMAC7.html)
JP2025166834A5 (cg-RX-API-DMAC7.html)
Ferko et al. Hyperattenuated recombinant influenza A virus nonstructural-protein-encoding vectors induce human immunodeficiency virus type 1 Nef-specific systemic and mucosal immune responses in mice
JP2025184979A5 (cg-RX-API-DMAC7.html)
Nagai Paramyxovirus replication and pathogenesis. Reverse genetics transforms understanding
JP2003510050A5 (cg-RX-API-DMAC7.html)
Ohgimoto et al. Sequence analysis of P gene of human parainfluenza type 2 virus: P and cysteine-rich proteins are translated by two mRNAs that differ by two nontemplated G residues
EP3805392A2 (en) Nucleic acid sequence expressing sars-cov-2 virus antigen peptide and use thereof
AU2004245859B2 (en) Cell surface expression vector of SARS virus antigen and microorganisms transformed thereby
JP2007513634A5 (cg-RX-API-DMAC7.html)
JP2022502077A5 (cg-RX-API-DMAC7.html)
JP2020536489A5 (cg-RX-API-DMAC7.html)
JP2018515096A5 (cg-RX-API-DMAC7.html)
JP2007537761A (ja) Tc−83由来アルファウイルスベクター、粒子および方法
JP2007502101A5 (cg-RX-API-DMAC7.html)
JPH09322781A5 (cg-RX-API-DMAC7.html)
JP2002510494A5 (cg-RX-API-DMAC7.html)
JP2002542827A5 (cg-RX-API-DMAC7.html)
RU2733831C1 (ru) Искусственный ген, кодирующий бицистронную структуру, образованную последовательностями рецептор-связующего домена гликопротеина S коронавируса SARS-CoV-2, P2A-пептида и гликопротеина G VSV, рекомбинантная плазмида pStem-rVSV-Stbl_RBD_SC2, обеспечивающая экспрессию искусственного гена и рекомбинантный штамм вируса везикулярного стоматита rVSV-Stbl_RBD_SC2, используемого для создания вакцины против коронавируса SARS-CoV-2
JP2022513326A5 (cg-RX-API-DMAC7.html)
JP2025503468A5 (cg-RX-API-DMAC7.html)
JP2020534284A5 (cg-RX-API-DMAC7.html)
JP2023542297A5 (cg-RX-API-DMAC7.html)
JP2023522708A5 (cg-RX-API-DMAC7.html)
WO2021207848A1 (en) Mers-cov vaccine